Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06876662 · ClinicalTrials.gov registry record · Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
A Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 279
- Enrollment target
- 20
- Study locations
NCT06876662: Recruiting Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company.
NCT06876662 is a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 279 participants, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06876662, a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 279 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Conditions Studied
Interventions
- DRUG Pirtobrutinib
Study Locations (20)
New York
- Cayuga Cancer Center - Ithaca
- Northwell Health - Lake Success
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
Florida
- Sylvester Comprehensive Cancer Center - Miami
- Florida Cancer Specialists - Sarasota
Other
- Flinders Medical Centre - Adelaide
- Peter MacCallum Cancer Centre - Melbourne
Georgia
- The Emory Clinic - Atlanta
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic- Minnesota - Rochester
Nebraska
- University Of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2032-12 |
| Phase | Phase 4 |
What NCT06876662 shows while recruiting
NCT06876662 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (55% higher).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Pirtobrutinib is the first listed.
NCT06876662 names 20 study sites across 15 states, led by New York, Florida, Other.
Frequently Asked Questions
What is clinical trial NCT06876662 about?
NCT06876662 is a clinical study titled "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma". Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stud...
What is the current status of trial NCT06876662?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 279 participants. The study started on 2025-05-20. Estimated completion is 2032-12.
What conditions does trial NCT06876662 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06876662?
The interventions under investigation include: Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06876662?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06876662 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06876662's enrollment target sits among peer trials
279 31st of 187 higher than 156 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RECRUITING · Phase 4
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI